Diagnoptics Technologies BV

Aarhusweg 4-9, 9723 JJ Groningen

Telephone +31 50 5890612
Fax +31 50 5890613

This company is co-exhibitor of
Task Force Health Care


Hall map

MEDICA 2016 hall map (Hall 15): stand F55

Fairground map

MEDICA 2016 fairground map: Hall 15

Our range of products

Product categories

  • 03  Diagnostics
  • 03.01  Clinical chemistry
  • 03.01.14  Rapid tests - clinical chemistry

Rapid tests - clinical chemistry

  • 03  Diagnostics
  • 03.01  Clinical chemistry
  • 03.01.14  Rapid tests - clinical chemistry
  •  Point of care - testing systems

Point of care - testing systems

Our products

Product category: Rapid tests - clinical chemistry, Point of care - testing systems


Diabetes screening
Diab spot is a non-invasive test to identify people at risk for diabetes or pre-diabetes without overnight fasting, a blood draw, or waiting for a lab result.

Diabetes mellitus is now one of the most common diseases globally with an estimated 285 million affected persons worldwide and 344 million persons with pre-diabetes. Each year, another 7 million people develop diabetesI and 3.8 million deaths worldwide are linked directly to diabetes related causes. The estimate is that at least one third of the patients with diabetes is undiagnosed.

Diabetes complications are very common. A large proportion of diabetics (50% or more in some studies) have at least one complication present at the time of diagnosis. In order to reduce diabetes associated complications and mortality there is a great need for screening and monitoring methods to assess the risk of diabetes and diabetic complications. If (pre-)diabetes is detected early, with only lifestyle intervention, or with medication the development of diabetes and its complications can be postponed or even prevented.

More Less

About us

Company details

Established in 2003, Diagnoptics is the pioneer and inventor of cutting edge diagnostic devices that can non-invasively diagnose and assess cardiovascular risk and risk of diabetes. Its technological advance in detecting fluorescence of Advanced Glycation Endproducts (AGEs) has led to the invention of the AGE Reader - a state of art diagnostic device which can determine the tissue accumulation of AGEs in 12 seconds.

AGEs are essential biomarkers of metabolic and glycemic stress and have been implicated as causative factors in the progression of a host of age-related diseases, such as atherosclerosis, diabetes, renal failure and Alzheimer. The amount of AGEs in tissue serves as an important cardiovascular risk predictor. The AGE Reader measurements allows the doctor to adjust the treatment for high-risk patients as soon as possible.

More Less

Company data

Export content

> 75%

Number of employees




Area of business
  • Electromedical equipment / Medical Technology
  • Diagnostics